WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

This group comprises preparations used in the treatment of malignant neoplastic diseases, and immunomodulating agents.

Corticosteroids for systemic use, see H02.


L01 ANTINEOPLASTIC AGENTS

Combination products are classified in L01XY - Combinations of antineoplastic agents.

Detoxifying agents used in connection with high dose treatment of antineoplastic agents are classified in V03AF (e.g. calcium folinate).

Radiopharmaceuticals used in the treatment of cancer are classified in V10X.

No DDDs have been established because of highly individualised use and wide dosage ranges. The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.

The consumption of the antineoplastic agents is in some countries measured in grams. This is recommended as a method to be used internationally for these particular agents.

L02 ENDOCRINE THERAPY

Estrogens and progestogens used specifically in the treatment of neoplastic diseases are classified in this group. This means that some strengths may be classified in this group, while remaining strengths are classified in G03 - Sex hormones and modulators of the genital system.

The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).

L03 IMMUNOSTIMULANTS

Immunosuppressants, see L04A.

L04 IMMUNOSUPPRESSANTS

Immunosuppressants are defined as agents that completely or partly suppress one or more factors in the immunosystem.

Last updated: 2018-12-13